Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Show more

Location: One Kendall Square, Cambridge, MA, 02139, United States | Website: https://www.camp4tx.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

27.21M

52 Wk Range

$1.30 - $12.30

Previous Close

$1.35

Open

$1.40

Volume

51,353

Day Range

$1.40 - $1.44

Enterprise Value

-12.13M

Cash

49.32M

Avg Qtr Burn

-12.18M

Insider Ownership

35.41%

Institutional Own.

56.56%

Qtr Updated

03/31/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
CMP-CPS-001 Details Urea Cycle Disorder	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.